Table 2.

Approved COPD indications in the EU and US for some LABA/ICS combinations.

Drug	Daily dose	Indication
		EU	US
Fluticasone propionate/salmeterol	500/50 µg × 2	Symptomatic treatment of patients with COPD, with a FEV1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy	Not approved
Fluticasone propionate/salmeterol	250/50 µg × 2	Not approved	Twice-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema Also indicated to reduce exacerbations of COPD in patients with a history of exacerbations
Budesonide/formoterol	400/12 µg × 2	Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators	Not approved
Budesonide/formoterol	200/6 µg × 2	Not approved	Maintenance treatment of airflow obstruction in patients with COPD including chronic bronchitis and emphysema
Fluticasone furoate/vilanterol	100/25 µg	Symptomatic treatment of adults with COPD with a FEV1 < 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy	Long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema Also indicated to reduce exacerbations of COPD in patients with a history of exacerbations

COPD: Chronic obstructive pulmonary disease; FEV₁: Forced expiratory volume in 1 second; LABA: Long-acting β₂-agonist; LAMA: Long-acting muscarinic antagonist; ICS: Inhaled corticosteroids.